丙酸氟替卡松联合氯雷他定治疗变应性鼻炎合并支气管哮喘的疗效观察

目的观察在吸入丙酸氟替卡松鼻喷雾剂的基础上联合使用氯雷他定对变应性鼻炎合并支气管哮喘的疗效观察。方法 60例轻、中度支气管哮喘患者均给予丙酸氟替卡松喷鼻及氯雷他定口服,记录鼻炎症状评分及哮喘症状评分。结果治疗前鼻炎症状评分为（4.8±1.2）分,治疗后鼻炎症状评分为（2.1±0.8）分;治疗前哮喘症状评分为（4.6±0.29）分,治疗后哮喘症状评分为（2.2±0.7）分。两组比较,差异均有统计学意义（P〈0.01）。结论在吸入丙酸氟替卡松鼻喷雾剂的基础上联合使用氯雷他定可显著提高变应性鼻炎合并哮喘的疗效。     

丙酸氟替卡松鼻喷雾剂治疗过敏性鼻炎临床有效观察分析

目的 探究丙酸氟替卡松鼻喷雾剂治疗过敏性鼻炎临床有效。方法 收集2020年4月-2021年4月时间段内于我院诊治的过敏性鼻炎患者70例,据治疗方案不同分为两组,观察组(37例)与对照组(33例)。对照组以氯雷他定片治疗,观察组则基于对照组联用丙酸氟替卡松鼻喷雾剂。比对两组症状改善时间、临床疗效及安全性。结果 治疗后观察组治疗有效率高于对照组(P<0.05);观察组鼻塞、流涕、打喷嚏及鼻痒的症状改善时间、不良反应发生率均低于对照组(P<0.05)。结论 临床治疗过敏性鼻炎通过丙酸氟替卡松鼻喷雾剂可显著缓解症状,疗效及安全性均较高,值得广泛推广。     

丙酸氟替卡松吸入治疗小儿急性喉炎43例疗效观察

目的 探讨丙酸氟替卡松(辅舒酮)治疗小儿急性喉炎的疗效.方法 将85例急性喉炎患儿分为治疗组43例、对照组42例.两组在相同的基础治疗上,治疗组使用丙酸氟替卡松吸入治疗,对照组使用地塞米松静脉滴注治疗.结果 治疗组总有效率93.02％,对照组总有效率90.47％,两组比较差异无统计学意义(P＞0.05);治疗组呼吸困难、喉鸣、声嘶等症状和体征缓解时间较对照组明显缩短,差异有统计学意义(P＜0.05).结论 丙酸氟替卡松吸入治疗小儿急性喉炎,可使患儿症状很快得到缓解,病程缩短,疗效确切,值得临床推广应用.     

丙酸氟替卡松与孟鲁司特治疗儿童咳嗽变异性哮喘疗效观察

目的观察丙酸氟替卡松联合孟鲁司特治疗儿童咳嗽变异性哮喘的临床疗效。方法选取2011年8月-2012年4月在潍坊市妇幼保健院儿科就诊的70例儿童咳嗽变异性哮喘（CVA）患儿作为研究对象,随机分为2组,对照组30例,治疗组40例。对照组应用丙酸氟替卡松气雾剂吸入治疗,治疗组在此基础上加用孟鲁司特口服治疗。两组总疗程均为12周。结果治疗组咳嗽缓解、消失时间均比对照组缩短,差异有统计学意义（P〈0.05）。疗程结束后均随访6个月,治疗组复发2例,对照组复发7例,复发率治疗组明显低于对照组（P〈0.05）。结论丙酸氟替卡松联合孟鲁司特治疗儿童咳嗽变异性哮喘,其疗效表现出较好的协同作用。     

支气管哮喘应用孟鲁司特钠联合吸入丙酸氟替卡松治疗的临床分析

目的:探讨孟鲁司特纳联合吸入丙酸氟替卡松治疗支气管哮喘患者的临床应用和疗效。方法:选取我院在2011年1月至2013年1月收治的支气管哮喘患者60例,将所有患者随机分为观察组和对照组,对照组单独给予丙酸氟替卡松吸入治疗,观察组在此基础上联合孟鲁司特纳治疗。结果:1个疗程后,观察组FEV1和PEF的肺功能指标明显优于对照组,治疗总有效率(92.3%)明显大于对照组(80.0%),且P<0.05,两组治疗期间均未发生明显不良反应。结论:联合应用孟鲁司特纳和丙酸氟替卡松治疗支气管哮喘患者安全、有效,值得临床推广。     

丙酸氟替卡松治疗40例儿童咳嗽变异性哮喘的临床分析

目的：观察分析丙酸氟替卡松治疗儿童咳嗽变异性哮喘的临床疗效,总结其临床治疗经验及应用价值。方法：选取笔者所在医院2009年4月-2011年4月80例儿童咳嗽变异性哮喘的患儿,随机分为观察组与对照组,各40例,对照组采取常规治疗,观察组在常规治疗基础上采取丙酸氟替卡松气雾剂吸入治疗,观察对比两组治疗效果。结果：观察组显效21例,有效16例,无效3例,无明显不良反应出现,远期复发1例,总有效率为92.5%;对照组显效15例,有效14例,无效10例,无不良反应出现,远期复发6例,总有效率为75.0%,两组治疗效果、远期复发率比较差异有统计学意义（P〈0.05）。结论：丙酸氟替卡松治疗儿童咳嗽变异性哮喘的临床疗效显著,明显优于常规治疗,能够迅速缓解临床症状,减少远期复发,改善肺功能,且无明显不良反应,是治疗儿童咳嗽变异性哮喘较为安全可靠的药物,具有重要的临床应用价值。     

吸入丙酸氟替卡松干粉剂每日1000微克对支气管哮喘患者肾上腺皮质功能的影响

目的评价吸入丙酸氟替卡松干粉剂每日1000μg疗程6个月对支气管哮喘患者肾上腺皮质功能的影响。方法非急性发作期支气管哮喘患者30例，病情严重程度均为治疗前重度持续。均给予吸入沙美特罗，丙酸氟替卡松干粉剂（商品名：舒利迭，剂量：50μg／500μg）每日2次，疗程6个月。吸入治疗前后分别测定患者早晨8时的血浆皮质醇。结果30例患者吸入治疗前和治疗6个月后测得的早晨8时血浆皮质醇值分别为（223．04±77．70）μg/L和（193．54±74．64）μg/L，两组比较差异无统计学意义（P=0．16），且患者吸入治疗6个月后的早晨8时血浆皮质醇值在正常范围内。结论吸入丙酸氟替卡松干粉剂每日1000μg疗程6个月对支气管哮喘患者的肾上腺皮质功能未产生明显抑制作用。     

低温等离子联合丙酸氟替卡松喷鼻剂治疗过敏性鼻炎96例报告

目的观察等离子联合糖皮质激素治疗过敏性鼻炎的临床疗效。方法将96例过敏性鼻炎患者应用低温等离子射频消融后,给予丙酸氟替卡松喷鼻剂（辅舒良）治疗。结果随访3个月～1年,显效59例,有效35例,无效2例,总有效率为98％。结论等离子联合丙酸氟替卡松喷鼻剂治疗过敏性鼻炎有显著疗效。     

吸人小剂量沙美特罗／丙酸氟替卡松治疗咳嗽变异性哮喘的临床观察

目的：探讨吸入小剂量沙美特罗／丙酸氟替卡松治疗咳嗽变异性哮喘的临床效果。方法：选取咳嗽变异性哮喘患者96例,随机分为A、B两组：在常规治疗基础上,A组给予吸入沙美特罗／丙酸氟替卡松（50／100μg,2次／d）,B组给予吸入丙酸倍氯米松（250μg,2次／d）,经过8周的治疗后观察统计两组患者的咳嗽积分、PEF改善情况。结果：两组患者经2-4周的治疗后,A组患者的咳嗽积分、PEF改善率明显高于B组,比较差异有统计学意义（P〈0．05）;8周后两组咳嗽积分比较差异无统计学意义（P〉0．05）,但PEF比较差异有统计学意义（P〈0．05）。结论：小剂量沙美特罗／丙酸氟替卡松治疗咳嗽变异性哮喘可以缩短疗程,提高疗效,减轻患者的痛苦,优于单一应用糖皮质激素。     

孟鲁司特钠联合丙酸氟替卡松吸入治疗支气管哮喘的临床研究

目的 分析孟鲁司特钠联合丙酸氟替卡松吸入治疗支气管哮喘的临床疗效。方法 选取本院收治的86例支气管哮喘患者,分组运用随机数字表法,分对照组与观察组各43例。两组均接受对症治疗,对照组在此基础上提供丙酸氟替卡松吸入治疗,观察组以孟鲁司特钠联合丙酸氟替卡松治疗。比较两组疗效与肺功能。结果 观察组治疗总有效率95.34%(41/43),与对照组81.40%(35/43)相比较高,差异有统计学意义(Z=2.054,P=0.040);观察组治疗后的第1秒用力呼吸量,用力肺活量,呼气峰流速分别为(2.08±0.20)L、(2.39±0.10)L、(270.39±39.32)L/min,高于对照组的(1.86±0.13)L、(2.21±0.12)L、(289.48±37.48)L/min,差异有统计学意义(t=2.501、3.952、2.307,P=0.014、0.000、0.024)。结论 对支气管哮喘患者运用孟鲁司特钠联合丙酸氟替卡松治疗可有效提升临床疗效,改善患者肺功能。     

丙酸氟替卡松鼻喷雾剂联合西替利嗪治疗变应性鼻-鼻窦炎致成年人亚急性咳嗽56例临床分析

目的 探讨丙酸氟替卡松鼻喷雾剂联合西替利嗪治疗变应性鼻-鼻窦炎致成年人亚急性咳嗽临床疗效.方法 筛选由变应性鼻-鼻窦炎致亚急性咳嗽56例成年人患者,按随机数字表法分为治疗组与对照组,每组28例.对照组给予一般止咳化痰药复方甘草合剂,治疗组在此基础上给予丙酸氟替卡松鼻喷雾剂联合西替利嗪片,观察并记录用药前后咳嗽轻重程度及不良反应.结果 治疗组的总有效率为82.1％（23/28）,而对照组总有效率为53.6％（15/28）,治疗组疗效明显优于对照组,差异有统计学意义（P＜0.01）.结论 丙酸氟替卡松鼻喷雾剂联合西替利嗪治疗变应性鼻-鼻窦炎致成年人亚急性咳嗽效果良好,值得临床推广.     

Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France

A budget impact model was used to estimate the effect of introducing inhaled salmeterol/fluticasone propionate combination on asthma drug-related costs in France. The model is based on disease prevalence, drug use, drug acquisition cost and sales forecasting data specific to France. It takes the perspective of social security and has a time horizon of 1 year. All drug acquisition costs are adjusted for the average rate of reimbursement of asthma medications in France (77.3%). All costs are expressed in euros. The model shows that if patients receiving concurrent salmeterol plus fluticasone propionate (or budesonide plus formoterol switch to combined salmeterol/fluticasone propionate, the anticipated annual savings would be 2,691,580 and 1,916,966 euros, respectively. On a fixed budget 4067 additional patients could be treated if salmeterol/fluticasone propionate is substituted for concurrent salmeterol plus fluticasone propionate and an additional 2939 patients if the combination is used to replace concurrent budesonide plus formoterol. Overall, using sales forecasting data to estimate how many patients will switch to the new combination from their current therapy, it is estimated that the introduction of salmeterol/fluticasone propionate will increase the national expenditure in France on asthma medications by a maximum of 3%. This budget impact model shows that the introduction of inhaled salmeterol/fluticasone propionate combination is likely to have minimal impact on asthma-related medication costs in France. Moreover, the available data on the salmeterol/fluticasone propionate combination suggest that it is clinically effective, cost-effective and affordable to the French healthcare system.     

联合治疗合并过敏性鼻炎的支气管哮喘患者的临床分析

目的 观察糠酸莫米松鼻喷剂联合沙美特罗/丙酸氟替卡松干粉吸入剂对合并过敏性鼻炎的支气管哮喘患者的治疗效果.方法 56例合并过敏性鼻炎的支气管哮喘患者,随机分为两组,对照组28例,给予吸入沙美特罗/丙酸氟替卡松 50/250 μg,1吸/次,2次/d.试验组28例,在吸入美特罗/丙酸氟替卡松治疗基础上,同时给予糠酸莫米松鼻喷剂治疗,每个鼻孔各1喷,50 μg/喷,2次/d,治疗时间为3个月.分别于治疗前后观察哮喘控制测试（ACT）评分、用力肺活量（FVC）、第一秒呼气容积（FEV1）,比较不同治疗方法的疗效.结果 试验组比对照组能显著提高ACT评分,患者的FVC、FEV1亦有明显改善,差异有统计学意义（ P 〈0.05）.结论 联合治疗过敏性鼻炎和支气管哮喘比单纯治疗支气管哮喘能显著提高支气管哮喘患者的治疗效果,有效地提高患者的生存质量.     

大蒜油治疗过敏性鼻炎临床观察

目的观察大蒜油治疗过敏性鼻炎（AR）的临床疗效。方法将81例AR患者分为2组,综治法组在对照组基础上加服用大蒜油疗法治疗。结果综治组疗效明显优于对照组。结论大蒜油对AR具有显著疗效。     

沙美特罗联合替卡松粉治疗咳嗽变异型哮喘临床效果分析

目的:观察沙美特罗联合替卡松粉治疗咳嗽变异型哮喘的临床效果。方法:入选的66例咳嗽变异型哮喘按住院号随机分为2组,治疗组36例应用沙美特罗联合替卡松粉治疗,对照组30例应用常规对症及支持治疗。结果:两组经治疗后,治疗组的总有效率明显高于对照组(P<0.05)。且治疗组的咳嗽、咳痰、喘息和肺部哮鸣音消失时间与对照组比较均明显缩短,差异有统计学意义(P<0.05)。结论:沙美特罗联合替卡松粉治疗咳嗽变异型哮喘疗效确切,可改善症状及体征,值得推广。     

Prevalence of bronchial asthma and allergic rhinitis in Istanbul school children

The aim of this study was to determine the prevalence of asthma, allergic rhinitis and their related symptoms in Istanbul and to investigate the effect of socioeconomic status on the prevalence of asthma and allergic rhinitis and whether there are differences between the prevalence of childhood asthma in the same and different regions as found in previous studies and our own. The study period was the 1996–1997 school year in three primary schools in Istanbul. For proportional representation of high, middle, and low socioeconomic levels, the schools were selected from three different regions of Istanbul. A translated version of the International Study of Asthma and Allergies in Childhood (ISAAC) was used. The questionnaire was distributed to the parents of 2600 students aged 6–15 years. All of the 2276 children whose parents responded were included in the survey. The overall cumulative and current prevalences of wheezing were 13.7 and 7.2% respectively and the overall cumulative prevalence of allergic rhinitis was 17.6%. There was no statistically significant difference between asthmatics and non-asthmatics by sex, socioeconomic status and passive smoking. Family history of atopy was found to be significantly higher in asthmatics. Although there are differences in the results of studies concerning the prevalence of asthma and allergic rhinitis not only between different countries but also between different regions of the same city, by using a standardized international method, the actual values may be obtained.     

Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD

BACKGROUND: Previous studies on inhaled steroid and long-acting beta2-agonist combination products may not be representative for the asthma and chronic obstructive pulmonary disease (COPD) patients in family practice. OBJECTIVES: To compare in a group of doctor-diagnosed patients with asthma or COPD, the effects of a lower dose of fluticasone in a combination product with salmeterol with conventional treatment (i.e. a higher dose of fluticasone), both supplemented with as-needed use of a short-acting bronchodilator. METHODS: The study was a 12-week multicentre, randomized controlled, double-blind trial. In all, 41 family practices recruited 137 patients diagnosed with asthma and 40 patients diagnosed with COPD. Primary outcome was the forced expiratory volume in 1 second (FEV1) as percentage of predicted. Morning peak expiratory flow (PEF), symptom-free days, health status [Asthma Quality of Life Questionnaire (AQLQ) and St. George's Respiratory Questionnaire (SGRQ)], exacerbations, use of short-acting bronchodilators and adverse events were secondary outcomes. RESULTS: FEV1% predicted increased 2.6% (SD 8.3) in fluticasone/salmeterol- and 0.01% (SD 6.6) in fluticasone-treated patients (overall: P=0.036, asthma: P=0.025 and COPD: P=0.700). PEF increased in favour of fluticasone/salmeterol in asthma patients only (P=0.016). Fluticasone/salmeterol-treated asthma patients had 1.1 more symptom-free days per week (P=0.044); no such effect was observed for COPD (P=0.769). There were no differences in total AQLQ and SGRQ scores, exacerbations, use of reliever puffs or adverse effects. CONCLUSIONS: In family practice patients diagnosed with asthma, several treatment goals were better achieved with a lower dose of fluticasone and salmeterol in a combination product than with a higher dose of fluticasone. We found no differences between the two approaches for patients with COPD.     

过敏性鼻炎及哮喘患者吸入性过敏原调查

目的 通过对百色市呼吸道变态反应性疾病过敏性鼻炎、哮喘患者进行吸入性过敏原检测及分析,筛查该市常见吸入性过敏原.方法 采用皮肤点刺诊断试剂盒,对210例儿童患者和200例成人患者的吸入性过敏原进行检测分析.结果 儿童患者中过敏原阳性检出209例(占99.52％),以户尘螨、犬毛、蟑螂过敏原的阳性率最高,分别检出146例(占69.52％)、131例(占62.28％)、127例(占60.48％);成人患者中过敏原阳性检出192例(占96.00％),以粉尘螨、户尘螨和芒果花粉过敏原的阳性率最高,分别检出124例(占62.00％)、113例(占56.50％)、89例(占44.50％).结论 户尘螨、犬毛、蟑螂及粉尘螨、户尘螨、芒果花粉分别与该市儿童及成人患者呼吸道变态反应性疾病有关.